The Fed’s interest rate pause, closed capital markets, the tariff storm, and mass layoffs at the U.S. FDA create a ...

The ongoing trade conflict and increasing economic concerns weigh heavily on earnings expectations. Yet, forecasts for the US ...

Following competitor Novartis, pharma giant Roche also announces massive investments in the United States. Swiss jobs and ...

After Accelleron, ABB is preparing its next billion dollar Spin-off. The new CEO is making his mark and delivers good results ...

Investors remained cautious after Donald Trump’s far-reaching tariff exemptions at the weekend – including Apple. Meanwhile, ...

Philip Morris shares have risen by more than 50% in the past twelve months – the transformation is going well. In an ...

The pharmaceutical company will build six new production sites and one for research and development in the USA. This will ...

Sensirion does not see itself affected by US tariff policy. New regulation is driving the sensor specialist’s business this ...

Following the recent near-financial crash, calls to exclude US government bonds from banks’ capital ratios are growing louder ...

The US insurer Willis Towers Watson is an alternative to defensive US stocks from the food industry. The business is ...

Six investment professionals tell our readers how to navigate in view of new US trade barriers. Today Philipp Lienhardt, Head ...

The violent market movements are a stress test for stocks rated as «immune to fluctuations». Some withstand the turbulences ...